Cardiovascular effects of mirabegron
Crossref DOI link: https://doi.org/10.1038/nrurol.2017.113
Published Online: 2017-07-11
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Andersson, Karl-Erik
Text and Data Mining valid from 2017-07-11
Article History
First Online: 11 July 2017
Competing interests
: K-E.A. declares that he is a consultant and/or on the advisory board for Allergan, Astellas and Ferring.